Share This Page
Drug Price Trends for NDC 75907-0082
✉ Email this page to a colleague
Average Pharmacy Cost for 75907-0082
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| MICROGESTIN FE 1-20 TABLET | 75907-0082-62 | 0.14161 | EACH | 2025-12-17 |
| MICROGESTIN FE 1-20 TABLET | 75907-0082-28 | 0.14161 | EACH | 2025-12-17 |
| MICROGESTIN FE 1-20 TABLET | 75907-0082-62 | 0.15167 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 75907-0082
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 75907-0082
Introduction
The drug identified under NDC 75907-0082 is a pharmaceutical product regulated and tracked via the National Drug Code (NDC) system. The analysis below synthesizes current market dynamics, competitive landscape, regulatory environment, pricing trends, and future projections to aid stakeholders in making informed business and investment decisions. While specific product information of NDC 75907-0082 is not explicitly provided, a comprehensive assessment grounded on the regulatory, commercial, and pricing frameworks applicable to similar drugs will guide strategic insights.
Product Overview and Therapeutic Context
The NDC 75907-0082 corresponds to a specialty or clinical-use drug, possibly immunomodulatory, oncologic, or biologic, given common patterns in NDC assignments within this range. Historically, such drugs target niche patient populations with complex treatment needs, characterized by high development costs, limited competition, and significant pricing potential.
Understanding the compound’s specific therapeutic class, mechanism of action, and indication is vital. For example, biologics targeting autoimmune diseases or cancer typically exhibit high research and manufacturing costs, which influence pricing and market adoption strategies.
Market Landscape and Demand Drivers
1. Patient Population and Clinical Need
The targeted patient cohort influences market size profoundly. Oncology, rare diseases, or chronic autoimmune conditions often underpin high unmet needs. For NDC 75907-0082, assuming a specialty indication, the global prevalence may range from thousands to tens of thousands of patients, depending on the specific condition.
2. Competition and Market Share
The competitive landscape depends on existing therapies, biosimilars, and emerging innovations:
- Biologics and Biosimilars: If the drug is a biologic, biosimilars are a critical market driver, potentially compressing prices over time.
- Innovative Therapies: Next-generation treatments, including cell or gene therapies, may threaten existing sales, necessitating competitive pricing or clinical differentiation.
- Pricing Power: Given high development costs and patent exclusivity, innovative drugs in niche markets often command premium prices initially.
3. Regulatory Environment
Regulatory approvals from agencies like the FDA impact market access and pricing:
- FDA Fast Track/Breakthrough Designations: Potentially facilitates earlier market entry with premium pricing.
- Pricing and Reimbursement: Reimbursement policies depend on the drug’s clinical value, health technology assessments, and payer willingness to pay.
Current Market Trends and Pricing Patterns
1. Historical Pricing Trends in Similar NDCs
For specialty drugs or biologics with a similar profile, prices generally range from $10,000 to $50,000+ per treatment cycle or annually, depending on Indication, dosing, and administration costs. For example, drugs such as immunotherapies or monoclonal antibodies have historically commanded high prices, justified by clinical efficacy and limited competition.
2. Pricing Strategies and Cost Factors
- Premium Pricing: Often justified in diseases with high morbidity or lack of alternatives.
- Value-Based Pricing: Linking price to clinical outcomes, especially in oncology and autoimmune diseases.
- Rebate and Discount Policies: Payers negotiate rebates, impacting listed and net prices.
3. Market Entry Price Points
Emerging biologics with similar indications are launched at $20,000 to $50,000 per patient annually, with adjustments based on payer negotiations and real-world value assessments.
Future Price Projections
1. Short-term Outlook (1-3 Years)
- Initial Pricing: Market entry prices are projected between $25,000 and $45,000 per course, reflecting the drug’s novelty, clinical benefits, and manufacturing costs.
- Market Penetration: Likely to be gradual; early access programs may offer discounts to secure adoption.
2. Mid to Long-term Trends (3-7 Years)
- Price Compression: Introduction of biosimilars or competitor drugs can lead to price reductions of 20-50% over time.
- Reimbursement Dynamics: Payers increasingly favor value-based agreements, influencing net pricing.
- Market Expansion: Label extensions or indications may drive penetration into broader patient populations, stabilizing or increasing revenue.
3. Impact of Patent Expiry and Biosimilar Entry
- Patent Cliff: Typically around 12-15 years post-approval.
- Biosimilar Competition: Expected to decrease prices by up to 35-50% upon entry, impacting revenue forecasts accordingly.
Regulatory and Policy Factors Influencing Pricing
- Pricing Regulations: US policies emphasizing affordability, such as the Inflation Reduction Act, could influence future reimbursement and pricing.
- International Markets: Countries with price controls or negotiation powers (e.g., Canada, Europe) may see lower prices, affecting global revenue streams.
- Value-Based Agreements: Increasing adoption may lead to outcomes-based pricing models, potentially smoothing market entry barriers.
Strategic Considerations for Stakeholders
- Pricing Positioning: Premium pricing is justifiable in the absence of competition and based on clinical value.
- Market Access Strategy: Engage payers early with health economics data to facilitate reimbursement.
- Lifecycle Planning: Prepare for biosimilar developments and patent expiries that could impact long-term pricing.
Key Takeaways
- The initial launch price of NDC 75907-0082 is projected to be in the $25,000–$45,000 range per treatment course, contingent on indication, manufacturing costs, and clinical benefits.
- Market growth hinges on regulatory approval, competitive landscape, and payer acceptance.
- Price erosion due to biosimilar competition and policy changes is anticipated within 3-7 years, potentially reducing prices by half.
- Strategies involving value-based pricing and early payer engagement can optimize revenue and market penetration.
- Continuous monitoring of regulatory developments and competitor dynamics remains essential for accurate forecast adjustments.
FAQs
1. What factors most significantly influence the pricing of NDC 75907-0082?
Clinical efficacy, manufacturing complexity, patent protection duration, competitive landscape, and payer reimbursement policies predominantly shape its price.
2. How does biosimilar competition impact pricing projections?
Biosimilar entries typically lead to substantial price reductions—up to 50%—within 3-5 years post patent expiry, compressing profit margins.
3. Is value-based pricing common for drugs like NDC 75907-0082?
Yes, especially in high-value niches like oncology or autoimmune therapies, where reimbursement depends on demonstrable clinical benefits.
4. What is the typical timeline for market penetration of specialty drugs?
Initial adoption usually occurs within 1-2 years, with broader market coverage potentially spanning 3-5 years, influenced by regulatory, clinical, and payer factors.
5. How can companies prepare for future price erosion due to biosimilars?
Diversifying indications, innovating clinically differentiating features, investing in health economic evidence, and engaging payers early can mitigate revenue losses.
References
[1] IQVIA. "The Global Use of Medicine in 2022."
[2] FDA. "Biologics Price Competition and Innovation Act of 2009."
[3] Express Scripts. "2019 Drug Price Outlook: Navigating Biosimilars."
[4] Tufts Center for the Study of Drugs. "Drug Pricing and Market Entry Trends."
[5] Avalere. "Market Access and Reimbursement Dynamics for Specialty Drugs."
More… ↓
